Home

2016 BCOP Recertification

Upcoming Events


HOPA News

Check out the latest edition of HOPA News!

HOPA News Volume 16 issue 2

Latest Discussions

HOPA Bulletin

  • With the approval of more than a dozen immunotherapies and targeted therapies for the treatment of cancer, patients have more options than ever before to treat their disease. However, the risk of adverse events is always present. With immunotherapy, and when you include combination therapy with a targeted medication, 30-60 percent of patients will have a hair, skin, or nail reaction, according to Anisha Patel, MD, FAAD, an associate professor of dermatology and internal medicine at The University of Texas MD Anderson Cancer Center in Houston.

Getting Started

Check out our user guide for further information.

Connect With Us